From pills to new uses, here's what Eli Lilly’s top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
STAT16h
How much weight loss is too much? Pharma is pushing the limit with new obesity drugs
One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...
Zepbound for Weight Loss
The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...
Rolling Out2d
This weight loss drug reduces heart failure risk
A groundbreaking study shows how Zepbound, a popular weight loss medication, could become a key treatment for heart failure ...
When online weight-loss drugs are too good to be true
A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...
MarketWatch4d
Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...
Trump's reciprocal tariffs would hit these European Union products that Americans buy the hardest
Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...